MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

Search

Simulations Plus Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

19.89 6.19

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.6

Max

20.02

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.4M

676K

Pardavimai

961K

18M

P/E

Sektoriaus vid.

48.528

87.826

Pelnas, tenkantis vienai akcijai

-0.034

Dividendų pajamingumas

0.48

Pelno marža

3.67

Darbuotojai

212

EBITDA

-3M

2.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+0.48% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.48%

2.26%

Kitas uždarbis

2026-04-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

13M

381M

Ankstesnė atidarymo kaina

13.7

Ankstesnė uždarymo kaina

19.89

Naujienos nuotaikos

By Acuity

50%

50%

183 / 361 reitingas Healthcare

Simulations Plus Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-13 19:05; UTC

Pagrindinės rinkos jėgos

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

2026-01-13 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Japan Election Hopes -- Market Talk

2026-01-13 23:41; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-13 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

2026-01-13 23:13; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

2026-01-13 23:10; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

2026-01-13 23:03; UTC

Rinkos pokalbiai

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

2026-01-13 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

2026-01-13 21:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

2026-01-13 21:15; UTC

Įsigijimai, susijungimai, perėmimai

VERSANT Completes Acquisition Of Free TV Networks >VSNT

2026-01-13 21:08; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

2026-01-13 20:39; UTC

Rinkos pokalbiai

Silver Settles at Another New High -- Market Talk

2026-01-13 20:21; UTC

Rinkos pokalbiai

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

2026-01-13 20:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

2026-01-13 19:08; UTC

Įsigijimai, susijungimai, perėmimai

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

2026-01-13 19:03; UTC

Uždarbis

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

2026-01-13 18:50; UTC

Uždarbis

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

2026-01-13 17:54; UTC

Rinkos pokalbiai

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

2026-01-13 17:49; UTC

Rinkos pokalbiai

Analysts Call For Potential Record Ethanol Output -- Market Talk

2026-01-13 17:38; UTC

Rinkos pokalbiai

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 17:19; UTC

Rinkos pokalbiai

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

2026-01-13 17:15; UTC

Rinkos pokalbiai

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Akcijų palyginimas

Kainos pokytis

Simulations Plus Inc Prognozė

Kainos tikslas

By TipRanks

0.48% į viršų

12 mėnesių prognozė

Vidutinis 19 USD  0.48%

Aukščiausias 19 USD

Žemiausias 19 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Simulations Plus Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

2

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

183 / 361 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat